Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 6/20 | 0.41 |
| ▸ | IDO1 | P14902 | 2/20 | 0.39 |
| ▸ | TDO2 | P48775 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | NR1D1 | P20393 | 1/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.38 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.37 |
| ▸ | GLS | O94925 | 1/20 | 0.37 |
| ▸ | STS | P08842 | 2/20 | 0.36 |
| ▸ | FAAH | O00519 | 1/20 | 0.36 |
| ▸ | KAT8 | Q9H7Z6 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9994672 | 0.84 | SCD5 (0.43) | USP30PKMGPR119 | |
| SCHEMBL345745 | 0.76 | SCD5 (0.35) | USP30PKMGPR119 | |
| SCHEMBL345095 | 0.76 | PKM (0.38) | USP30PKMGPR119 | |
| SCHEMBL345715 | 0.74 | KDM4E (0.46) | USP30IDO1TDO2KDM4EPKM | |
| SCHEMBL25293821 | 0.69 | USP30 (0.50) | USP30IDO1TDO2KDM4EPKM | |
| SCHEMBL31362180 | 0.69 | USP30 (0.50) | USP30IDO1TDO2KDM4EPKM | |
| SCHEMBL3564630 | 0.69 | NR1H2 (0.48) | USP30IDO1TDO2KDM4EPKM | |
| SCHEMBL1996182 | 0.69 | NR1H2 (0.48) | USP30IDO1TDO2KDM4EPKM | |
| SCHEMBL3568388 | 0.69 | NR1H2 (0.48) | USP30IDO1TDO2KDM4EPKM | |
| SCHEMBL13326526 | 0.68 | GPR119 (0.43) | USP30IDO1TDO2KDM4EPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8716289-B2 | Carbamate derivatives of alkyl-heterocycles, preparation thereof and therapeutic use thereof | SANOFI (FR) | 2014-05-06 | — | — | US | disclosed |
| US-20120015950-A1 | CARBAMATE DERIVATIVES OF ALKYL-HETEROCYCLES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015950-A1 | CARBAMATE DERIVATIVES OF ALKYL-HETEROCYCLES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | INTS9, CDK8, SCN8A | USP30 4160/4885IDO1 2646/4885TDO2 2484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.